Chicago-based GTCR investment funds have reported a significant reduction in their holdings of Sotera Health Co (NASDAQ:SHC). According to filings with the Securities and Exchange Commission, the transactions took place on May 13, 2026. The sale involved 12,735,301 shares of common stock.
The disposition was executed at a price of $15.168 per share, resulting in total proceeds valued at approximately $193,169,045. These transactions were structured as part of an underwritten public secondary offering. Following the completion of this sale, the reporting GTCR entities confirmed that they hold no remaining shares of Sotera Health Co common stock.
The current market data for SHC indicates a trading price of $15.27 and a total market capitalization of $4.42 billion. While some analysis suggests that Sotera Health may be undervalued at its present levels, citing a low Price-to-Earnings (P/E) ratio relative to anticipated near-term earnings growth, the recent institutional selling adds a layer of complexity to investor sentiment.
The reporting parties involved in this transaction included several GTCR entities: specifically, GTCR Fund XI/A LP, GTCR Fund XI/C LP, GTCR Co-Invest XI LP, GTCR Partners XI/A&C LP, and GTCR Investment XI LLC. These listed organizations were identified as directors and ten percent owners of Sotera Health Co.
The structure of the holdings was detailed, noting that shares were held indirectly by the GTCR XI Funds (comprising GTCR Fund XI/A LP, GTCR Fund XI/C LP, and GTCR Co-Invest XI LP). Furthermore, GTCR Partners XI/A&C LP functions as the general partner for both Fund XI/A and Fund XI/C. Separately, GTCR Investment XI LLC is designated as the general partner for Co-Invest XI and Partners XI/A&C LP. It was also noted that GTCR Investment XI LLC operates under a board of managers, meaning no single individual possesses sole voting or dispositive authority over these shares. For regulatory purposes, each reporting person involved in this sale is considered a director-by-deputization for Section 16 compliance.
These institutional sales occurred against a backdrop of recent positive corporate announcements for Sotera Health. The company recently reported robust financial results for the first quarter of 2026, surpassing market expectations for both revenue and earnings. Specifically, SHC posted an earnings per share (EPS) of $0.18, which exceeded the forecast of $0.17. Revenue reached $280.05 million, outperforming the expected figure of $270.78 million.
Despite these strong financial indicators and positive operational news, the company's stock experienced a decline during premarket trading. Adding to the activity, affiliates associated with Warburg Pincus LLC and GTCR LLC announced another secondary offering involving 31,838,253 shares of Sotera Health’s common stock. Sotera Health clarified that it would not be receiving any proceeds from this subsequent sale; rather, the funds generated were intended solely to cover the associated offering expenses.
Further analyst attention was highlighted by Wolfe Research, which adjusted its price target for SHC shares upward to $19 from a previous $20. The firm maintained an Outperform rating on the stock, citing favorable first-quarter results as justification for the adjustment. These varied developments reflect ongoing market activity and diverse viewpoints surrounding Sotera Health.
Risks
- Market Volatility Following Large Sales
- Uncertainty of Secondary Offering Proceeds Use
- Potential Disconnect Between Earnings and Stock Price
More from Insider Trading
Risks
- Market Volatility Following Large Sales
- Uncertainty of Secondary Offering Proceeds Use
- Potential Disconnect Between Earnings and Stock Price